Axitinib-Induced Hypothyroidism as a Predictor of Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma | Zendy

Shinya Takada | Zendy; Hirokazu Hashishita | Zendy; Satoshi Nagamori | Zendy; Masayuki Endo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Axitinib-Induced Hypothyroidism as a Predictor of Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma

Author(s) -

Shinya Takada,

Hirokazu Hashishita,

Satoshi Nagamori,

Masayuki Endo

Publication year - 2019

Publication title -

urologia internationalis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 53

eISSN - 1423-0399

pISSN - 0042-1138

DOI - 10.1159/000499089

Subject(s) - medicine , axitinib , sunitinib , renal cell carcinoma , levothyroxine , thyroid , thyroid carcinoma , hormone , endocrinology , oncology , gastroenterology , urology

The side effects of sunitinib, namely onset of hypertension and hypothyroidism, have been reported to be predictive biomarkers of treatment efficacy. However, the relationship between hypothyroidism and prolongation of survival in treatment with axitinib, a drug similar to sunitinib, has not yet been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research